BHR Investment

BHR Investment is a Shenzhen-based private equity fund manager focused on China-related cross-border M&A, value investing, state-owned enterprise reform, industrial upgrading and new economy opportunities. It invests across China and has also participated in later-stage venture financings involving Hong Kong companies, including AI-enabled biotechnology, oncology and pharmaceutical drug discovery. The firm has managed more than RMB 22 billion of investments, making it relevant to companies seeking growth, strategic expansion, transformation or acquisition-oriented capital in China-linked markets.